Regulatory perspectives on next-generation sequencing and complementary diagnostics in Japan
Sign Up to like & getrecommendations! Published in 2020 at "Expert Review of Molecular Diagnostics"
DOI: 10.1080/14737159.2020.1728256
Abstract: ABSTRACT Introduction The ‘one biomarker/one drug’ scenario is unsustainable because cancer is a complex disorder that involves a number of molecular defects. In the past decade, major technological advances have lowered the overall cost and… read more here.
Keywords: diagnostics japan; complementary diagnostics; regulatory perspectives; next generation ... See more keywords